Plasma hyaluronan-binding protein (PHBP), alternatively named factor VII activating protease, is a serine protease that can activate blood coagulation factor VII and the proenzyme form of urokinase-type plasminogen activator.
These findings suggest that pro-PHBP activation can proceed through multiple mechanisms depending on the kind of pathophysiological stimuli. 10, 11) Polyamine concentrations are higher in cells and tissues with inflammation and malignancy, where significant cell death is observed. Inflammatory responses are associated with an increase in vascular permeability. Thus, one of the possible sites of pro-PHBP activation is extravascular tissue with inflammation. Polyamines released from the damaged cells may play a role in the extravascular regulation of pro-PHBP activation. In this study, we attempted to identify a specific agent that can inhibit polyamine-promoted pro-PHBP autoactivation.
MATERIALS AND METHODS
Materials Pro-PHBP was isolated from human plasma as described by Etscheid et al. 5) Briefly, human citrated plasma was fractionated on Q-Sepharose column chromatography in the presence of urea (6 M) , and fractions rich in pro-PHBP were further purified on Mono-Q column chromatography. The purified pro-PHBP preparation was stored in 6 M urea, in which pro-PHBP autoactivation/degradation was completely inhibited. The preparation was diluted just before assays with buffer A (50 mM Tris-HCl, pH 7.4, 75 mM NaCl, 5 mM CaCl 2 , and 0.05% (w/v) Tween 20). The active form of PHBP was prepared by incubating pro-PHBP (200 nM) in buffer B (50 mM Tris-HCl, pH 6.0, 150 mM NaCl, 10 mM CaCl 2 , and 0.1% (w/v) Tween 20) for 20 min at 37°C. The following proteins and chemicals were from commercial sources: human plasmin and alizarin from Wako Chemical (Osaka, Japan); factor Xa from Haematologic Technologies (Essex Junction, VT, U.S.A.); purpurin, emodin, spermidine, heparin, human thrombin, bovine trypsin, and e-poly-L-lysine from Sigma (St. Louis, MO, U.S.A.); and SPECTROZYME ® TH (STH; H-D-hexahydrotyrosyl-Ala-Arg-p-nitroanilide) and SPECTROZYME ® FXa (methoxycarbonyl-D-cyclohxylglycyl-Gly-Arg-p-nitroanilide-acetate) from American Diagnostica (Greenwich, CT, U.S.A.). Along with the supplier's information, the authenticity and purity of purpurin, emodin, and alizarin were examined by in-house analyses (HPLC and MS).
Assay for pro-PHBP Activation For the determination of the pro-PHBP autoactivation, 5 nM pro-PHBP in 50 ml of buffer A was incubated for 20 min at 37°C in the presence of an appropriate inducer and/or inhibitor. The concentrations of the inducers were: spermidin, 5 mM; heparin, 0.5 mg/ml; poly-L-lysine, 20 ng/ml. The active PHBP formed during the incubation was determined by adding 10 ml of the chromogenic substrate STH (0.6 mM) to the reaction mixture. The initial rate of STH hydrolysis (a release of p-nitroaniline) was determined kinetically by measuring the absorbance at 405 nm.
Pro-PHBP autoactivation can proceed in the absence of an inducer when the zymogen is incubated at a higher concentration. Thus, non-induced pro-PHBP autoactivation was assayed at the zymogen concentration of 20 nM.
Screening for Inhibitors of Pro-PHBP Autoactivation and Identification of Bikaverin Microbial cultures and a panel of selected natural products were tested for their activity to inhibit spermidine-induced pro-PHBP autoactivation. Assays were carried out by incubating pro-PHBP (5 nM) with a sample to be tested in buffer A containing STH (0.1 mM) and spermidine (5 mM). From the initial screening, the fungus Talaromyces wortmannii IFO 7238 was selected as a candidate that produced an active compound. For the production of the active compound, T. wortmannii was aerobically grown at 25°C for 5 d on a medium consisting of glucose (35 g/l), corn starch (10 g/l), soybean meal (20 g/l), peptone (5 g/l), fish meat extract (5 g/l), yeast extract (3 g/l), NaCl (2 g/l), K 2 HPO 4 (0.5 g/l), MgSO 4 · 7H 2 O (0.05 g/l), and the antifoam CB442 (Nippon Oil & Fat Co., Tokyo, Japan) (0.1%, v/v), pH 5.8. The cultured broth (5 l) was filtrated, and the resulting mycelia cake was washed with 3 l of MeOHHCl, pH 3, followed by extraction with 3 l of chloroform. The chloroform extracts were concentrated, dissolved in chloroform-MeOH (9 : 1), and subjected to preparative HPLC on an Inertsil PREP-ODS (250ϫ30 mm, GL Science, Tokyo, Japan). The column was developed with a linear gradient of water (from 21 to 0%) in chloroform-methanoltrifluoroacetic acid (50 : 100 : 0.1) % for 15 min at 25 ml/min. A crystalline material (40 mg) was obtained from a fraction eluting as a peak at 8.8 min. The compound was identified as bikaverin ( Fig. 1) Assay for Other Proteases The following proteases were assayed at 37°C in buffer A at the enzyme and substrate concentrations described below. Plasmin (20 nM) with Val-Leu-Lys-p-nitroanilide (0.1 mM); thrombin (0.25 IU/ml) with STH (0.1 mM); factor Xa (0.1 nM) with SPECTRO-ZYME ® Xa (0.1 mM); trypsin (50 pM) with STH (0.1 mM). Changes in absorbance at 405 nm were measured kinetically.
RESULTS AND DISCUSSION

Identification of Bikaverin from Screening of Natural Sources
We initially screened approximately 2000 microbial cultures for an inhibitor of pro-PHBP autoactivation induced by spermidine, and we found that a strain of the fungus T. wortmannii produced an active substance. We purified the active principle and identified it as bikaverin (Fig. 1 ) from spectroscopic and X-ray crystallographic analyses (see Materials and Methods for details). Bikaverin inhibited spermidine-induced pro-PHBP autoactivation with an IC 50 of 0.45 mM, while it also inhibited pro-PHBP autoactivation in the absence of an inducer (IC 50 ϭ2.5 mM) and enzyme activity of the active form of PHBP (IC 50 ϭ0.8 mM) (Fig. 1A) . It should be noted that the inhibition of PHBP, unlike the inhibition of pro-PHBP autoactivations, does not reach to 100% (but reach a plateau at 60% inhibition). It is likely that the inhibition of the active form of PHBP is due to an allosteric effect that partly limits the enzyme activity toward the synthetic substrate STH, while the allosteric effect on pro-PHBP results in a complete inhibition of its autoactivation regardless of the kind of an inducer.
Bikaverin did not affect the enzyme activity of thrombin and trypsin, serine proteases with a catalytic domain organization similar to that of PHBP. However, plasmin and factor Xa, other related serine proteases, which also had a similar serine protease domain, were inhibited by bikaverin with IC 50 of 3.2 and 8.8 mM, respectively (Fig. 1B) .
Identification of Purpurin as a Specific Inhibitor Next, a panel of natural compounds structurally related to bikaverin was screened for more specific inhibitors. Hits were tested for inhibition of active PHBP to exclude compounds inhibiting the protease activity itself. Selected compounds were further assayed for heparin-induced autoactivation of pro-PHBP. The final assay on heparin-induced autoactivation is based on the fact that the mechanism of heparininduced autoactivation, which involves pro-PHBP concentration on heparin, is different from that induced by spermidine, which induces the formation of pro-PHBP autoactivation complex. 10) These assays led to the identification of purpurin (Fig. 2) as a selective inhibitor of spermidine-induced pro-PHBP autoactivation.
As shown in Fig. 2A , purpurin inhibited spermidine-induced pro-PHBP autoactivation with an IC 50 of 6.6 mM, while the agent did not affect non-induced pro-PHBP autoactivation and the activity of PHBP at 30 mM. Like spermidine, poly-lysine is a positively-charged molecule that enhances pro-PHBP autoactivation, possibly employing a mechanism similar to that of spermidine. As expected, purpurin did inhibit poly-lysine-induced autoactivation (IC 50 ϭ25 mM), whereas the compound did not affect heparin-induced autoactivation (Fig. 2B) . Furthermore, purpurin showed a minimal effect on the activities of the other serine proteases, including plasmin, thrombin, factor Xa, and trypsin (Fig. 2G) .
Purpurin is classified into the family of anthraquinone natural products. Alizarin and emodin are closely related analogs, which differ from purpurin in the position or the number of the hydroxyl groups (Fig. 2) . In spite of their structural similarity to purpurin, the action of these compounds was weak and less specific. Alizarin, which lacked 4-OH of purpurin, inhibited spermidine-promoted pro-PHBP autoactivation with an IC 50 of 55 mM, but did not inhibit noninduced autoactivation and active PHBP (Fig. 2C) . However, the agent inhibited heparin-induced autoactivation at a concentration similar to that for the inhibition of the spermidineinduced one (IC 50 ϭ72 mM; Fig. 2D ). Emodin has three hydroxyl groups at positions 1, 3, and 8, which differ from those in purpurin (at positions 1, 2, and 4). At a high concentration (100 mM), emodin inhibited active PHBP as well as spermidine-induced pro-PHBP autoactivation (Fig. 2E) , but did not affect poly-lysine-induced or heparin-induced autoactivation (Fig. 2F) .
Thus, the position and/or the number of the hydroxyl group affect both the potency and selectivity of the anthraquinone inhibitors. Particularly, purpurin, which is ca. 8 times more potent than alizarin, only differs from alizarin at 4-OH. Moreover, the structural difference is related to the selectivity of the actions of the two anthraquinones: alizarin but nor purpurin inhibits heparin-induced pro-PHBP autoactivation.
In normal physiological conditions, PHBP circulates predominantly as pro-PHBP, and its activation is observed only after hepatic injury 7) or inflammation. 8) Thus, pro-PHBP activation may be a highly regulated process and a particular mechanism should be involved in pathophysiological pro-PHBP activation, possibly during inflammation. Polyamines are candidates for the mediators that induce pro-PHBP activation under such conditions. Effects of purpurin (A, B), alizarin (C, D), and emodin (E, F) on autoactivation of pro-PHBP in the presence of spermidine ('SPD-induced'), poly-lysine ('Poly-K-induced'), and heparin ('Heparin-induced'), as well as that in the absence of inducer ('Non-induced') or enzyme activity of active form of PHBP ('Active PHBP') were assayed in the presence of the indicated concentrations of each compounds. Panel E shows the summary of these results and the effects of purpurin and alizarin on the activity of plasmin, thrombin, factor Xa, and trypsin. The structures of the compounds are shown. Each value was obtained from experiments performed in triplicate. Error bar represents S.D.
